Insider Selling: Pyxis Oncology (NASDAQ:PYXS) Director Sells 13,896 Shares of Stock

Pyxis Oncology, Inc. (NASDAQ:PYXS) Director Rachel Humphrey sold 13,896 shares of the stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $1.03, for a total transaction of $14,312.88. Following the completion of the sale, the director directly owned 81,309 shares of the company’s stock, valued at $83,748.27. This represents a 14.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Pyxis Oncology Stock Up 5.1%

NASDAQ:PYXS traded up $0.07 during trading hours on Wednesday, hitting $1.43. 185,476 shares of the stock traded hands, compared to its average volume of 720,529. Pyxis Oncology, Inc. has a 1 year low of $0.83 and a 1 year high of $5.55. The company has a market cap of $89.03 million, a price-to-earnings ratio of -1.11 and a beta of 1.45. The stock has a 50 day moving average price of $1.52 and a 200 day moving average price of $2.51.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings data on Monday, March 23rd. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. The firm had revenue of $11.04 million during the quarter. Equities analysts forecast that Pyxis Oncology, Inc. will post -1.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PYXS has been the subject of a number of recent analyst reports. Wall Street Zen lowered Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Stifel Nicolaus dropped their price objective on shares of Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a research report on Tuesday. Royal Bank Of Canada dropped their price target on shares of Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Thursday, December 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Hedge Funds Weigh In On Pyxis Oncology

Several institutional investors have recently made changes to their positions in the company. J. Derek Lewis & Associates Inc. purchased a new position in shares of Pyxis Oncology during the fourth quarter valued at $61,000. XTX Topco Ltd lifted its stake in Pyxis Oncology by 1,533.0% in the fourth quarter. XTX Topco Ltd now owns 289,033 shares of the company’s stock worth $332,000 after acquiring an additional 271,334 shares during the period. Toronto Dominion Bank bought a new position in Pyxis Oncology during the 4th quarter worth about $86,000. Quadrature Capital Ltd bought a new position in Pyxis Oncology during the 4th quarter worth about $116,000. Finally, Maia Wealth LLC purchased a new position in Pyxis Oncology during the 4th quarter valued at about $25,000. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.